+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Japan Diabetes Care Devices Market - Growth, Trends, and Forecasts (2020-2025)

  • ID: 5023197
  • Report
  • May 2020
  • Region: Japan
  • 99 Pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Abbott Diabetes Care
  • Ascensia Diabetes Care
  • DEXCOM INC?
  • F. Hoffmann-La Roche Ltd
  • NOVO NORDISK AS
  • Terumo
The Japanese diabetes care devices market is expected to register a CAGR greater than 3.4% during the forecast period (2020-2025).
  • Diabetes has emerged as a global epidemic and has affected around 7 million people, in Japan. While Type 1 diabetes is caused as an immune system malfunction, Type 2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. Hence, Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be characterized as insulin-dependent diabetes. ​
  • The monitoring and management of blood glucose levels are on the rise, in order to avoid negative consequences, such as cardiovascular diseases, a blood disorder, blindness, kidney disorder, and many other conditions. ​

Key Market Trends

Rising Prevalence of Diabetes

The prevalence of diabetes is growing among all ages in Japan, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles. The prevalence of diabetes in adults is around 7.7%. The Japanese healthcare system has a few disease management programs conducted by the Japan Association for Diabetes Education and Care. Japan is one of the regional leaders in Asia-Pacific, in terms of diabetic public health policies. The country promotes public awareness and embraces preventive policies that focus on lifestyle and dietary adjustments, which can lessen the likelihood of adult-onset diabetes. ​

Insulin Cartridge in Reusable Pens Segment Accounted for the Major Share in the Market

In 2019, insulin cartridge in reusable pens segment had a share of 70.8% in the Japanese diabetes care devices market, and it is anticipated to register a CAGR of 2.74% during the forecast period. This is mainly due to the low price of devices because of more competition among local manufactures in Japan. ​ Insulin cartridges in reusable pens are known to be a needed extension to insulin pens. These devices are an upgraded version of the insulin vials. Most types of insulins are manufactured in the form of cartridges, thus, making it easily accessible. Insulin cartridges are more user-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers on-the-go.

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market. The major companies are partnering with each other to develop new technologies in diabetes care devices, which is likely to drive the market in the future. For instance, in February 2020, Abbott and Insulet partnered to integrate next-generation glucose sensing and automated insulin delivery technologies for seamless diabetes care. This collaboration may combine Abbott's continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon Automated Insulin Delivery System, to offer an accurate, easy-to-use, integrated digital health platform. ​

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Diabetes Care
  • Ascensia Diabetes Care
  • DEXCOM INC?
  • F. Hoffmann-La Roche Ltd
  • NOVO NORDISK AS
  • Terumo

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Monitoring Devices (Revenue and Volume, 2012-2025)
5.1.1 Self-monitoring Blood Glucose Devices (Hospital Use and Home Use)
5.1.1.1 Glucometer Devices
5.1.1.2 Blood Glucose Test Strips
5.1.1.3 Lancets
5.1.2 Continuous Glucose Monitoring Devices
5.1.2.1 Sensors
5.1.2.2 Durables (Receivers and Transmitters)
5.2 Management Devices
5.2.1 Insulin Delivery Devices
5.2.1.1 Insulin Pumps
5.2.1.1.1 Insulin Pump Monitor
5.2.1.1.2 Insulin Pump Reserviour
5.2.1.1.3 Insulin Ifusion Sets
5.2.1.2 Insulin Syringes
5.2.1.3 Insulin Disposable Pens
5.2.1.4 Insulin Cartridges in Reusable Pens
5.2.1.5 Jet Injectors
5.3 By Country
5.3.1 Japan (Revenue and Volume, 2012-2025)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2025)
6.2 Type 2 Diabetes Population (2012-2025)
7 REIMBURSEMENT POLICES (CGM and Insulin Pump)8 MARKET STRUCTURE (CGM and Insulin Pump)
9 COMPETITIVE LANDSCAPE
9.1 Company Profiles
9.1.1 Abbott Diabetes Care
9.1.2 F. Hoffmann-La Roche Ltd
9.1.3 Johnson & Johnson (LifeScan)
9.1.4 Arkray
9.1.5 Ascensia Diabetes Care
9.1.6 SANOFI
9.1.7 DEXCOM INC?
9.1.8 Medtronic
9.1.9 NOVO NORDISK AS
9.1.10 Becton Dickinson
9.1.11 Eli Lilly
9.1.12 Ypsomed Holding AG
9.1.13 Terumo
9.2 Market Share Analysis
9.2.1 CGM
9.2.1.1 Medtronic
9.2.1.2 Dexcom
9.2.1.3 Abbott Diabetes Care
9.2.2 Insulin Pump
9.2.2.1 Medtronic
9.2.2.2 Insulet Corporation
9.2.2.3 Tandem
9.2.2.4 F. Hoffmann-La Roche Ltd
9.2.2.5 Terumo
10 FUTURE OF THE MARKET
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Diabetes Care
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson (LifeScan)
  • Arkray
  • Ascensia Diabetes Care
  • SANOFI
  • DEXCOM INC​
  • Medtronic
  • NOVO NORDISK AS
  • Becton Dickinson
  • Eli Lilly
  • Ypsomed Holding AG
  • Terumo
Note: Product cover images may vary from those shown

Loading
LOADING...